scholarly journals Serum CA19 ‐9, CA ‐125 and CEA as tumor markers for mucinous ovarian tumors

2020 ◽  
Vol 46 (11) ◽  
pp. 2287-2291
Author(s):  
Arb‐aroon Lertkhachonsuk ◽  
Supree Buranawongtrakoon ◽  
Navamol Lekskul ◽  
Naparat Rermluk ◽  
Wei‐Wei Wee‐Stekly ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Mucinous Ovarian Tumors

scholarly journals Mass lesions of ovary - Tumor markers can be misleading

2014 ◽  
Vol 6 (3) ◽  
pp. 26-29
Author(s):  
Moothiringode Chitrabhanu Savithri ◽  
Usha Mary Abraham
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Ovarian Tumors ◽  
Treatment Modalities ◽  
Ca 125 ◽  
Medical Sciences ◽  
Ovarian Carcinomas ◽  
Ovary Tumor ◽  
Mass Lesions ◽  
Sex Cord Stromal Tumors

Background: Ovarian mass lesions could be neoplastic or non neoplastic. The less aggressive lesions should be distinguished from carcinomas which require extensive surgical procedures. CA-125 is a tumor marker used for evaluating ovarian carcinomas. In this series we found seven cases of sex cord stromal tumors (SCT) and endometriotic cysts with raised CA-125 levels, the highest value being 1540 IU/ml. Aims and Objectives: 1) To retrospectively evaluate cases which presented as mass lesions of ovary over a two year period along with CA-125 levels if available. 2) To find out the number of non carcinomatous lesions with elevation of the tumor marker CA-125. Materials and Methods: Total number of ovarian tumors and endometriotic cysts reported in the Department of Pathology, Amala Institute of Medical Sciences, Thrissur, Kerala, India in the two year period of 2012 and 2013 were retrospectively identified. CA-125 levels if available were noted. Results: Primary ovarian tumors comprised 180 cases, the rest being metastastic adenocarcinomas. There were 15 cases of SCT and 21 endometriotic cysts. CA 125 levels were increased in 2 cases each of granulosa cell tumors and fibrothecomas and 3 cases of endometriotic cysts. Highest value was 1540 IU/ml. Conclusion: Elevation of the tumor marker CA 125 often tricks the clinician into making a provisional diagnosis of carcinoma of ovary. It is important to understand the limitations in the interpretation of tumor markers so that more aggressive treatment modalities are avoided. DOI: http://dx.doi.org/10.3126/ajms.v6i3.10983  Asian Journal of Medical Sciences Vol.6(3) 2015 26-29 

scholarly journals Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Rosekeila Simões Nomelini ◽  
Taísa Morete da Silva ◽  
Beatriz Martins Tavares Murta ◽  
Eddie Fernando Candido Murta
Keyword(s):  
Tumor Markers ◽  
Blood Count ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Borderline Ovarian Tumor ◽  
Tumor Type ◽  
Borderline Ovarian Tumors ◽  
Stage Ib ◽  
Ca 19.9 ◽  
Stage Ia

The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n=13) and stage IB-IIIC (n=8). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC (P<0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.

Serum CA 125, Carcinoembryonic Antigen, and CA 19-9 as Tumor Markers in Borderline Ovarian Tumors

2000 ◽  
Vol 78 (1) ◽  
pp. 16-20 ◽  
Author(s):  
Mirjam J.A. Engelen ◽  
Henk W.A. de Bruijn ◽  
Harrie Hollema ◽  
Klaske A. ten Hoor ◽  
Pax H.B. Willemse ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Borderline Ovarian Tumors

scholarly journals Relationship between Serum Tumor Markers, CA-125, CEA, CA19-9, LDH, and βHCG with Histopathology and Age in Women with Ovarian Tumors

2020 ◽  
Vol 5 (4) ◽  
pp. 167-171
Author(s):  
Nilajkumar D Bagde ◽  
Madhuri N Bagde ◽  
Zamir A Lone
Keyword(s):  
Tumor Markers ◽  
Cross Sectional Study ◽  
Serum Markers ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Benign Tumors ◽  
Histopathological Analysis ◽  
Cross Sectional ◽  
Serum Tumor Markers

Introduction: Ovarian tumors pose a diagnostic predicament as it is difficult to differentiate benign from malignant without a histopathology report. Appropriate tumor markers may serve as diagnostic aid to better decision making in the management of these cases. We attempted to determine the relationship between age, serum markers, and histopathological sub types of ovarian tumors to help distinguish benign from malignant tumors.Methods: A retrospective cross sectional study of all cases with ovarian tumors that had available histopathology reports and tumor marker levels was done at a single centre. Variables examined were age, histopathology report and serum tumor markers CA-125, CEA, CA19-9, LDH, and βHCG. Results: Histopathological analysis revealed 26% teratomas, 28% cystadenomas, 14% corpus luteal cysts, 26% carcinomas and 6% endometriomas. CA-125 was the only marker that was significantly raised in malignant versus benign tumors (p=0.008) and increased with increasing age. All women with raised CEA reports had teratomas, and none with cancers had a raised CEA. CA19-9, LDH and βHCG were not significantly different in benign versus malignant tumors.Conclusions: CA-125 may be used as an adjuvant diagnostic tool for ovarian cancer in older women. The role of CEA as a marker for teratomas needs further evaluation.

scholarly journals Diagnosis and treatment characteristics of mucinous ovarian tumors

2021 ◽  
Vol 70 (2) ◽  
Author(s):  
Tudor Rotaru ◽  
◽  
Rotaru Ludmila ◽  
Daniela Mocan ◽  
Nicu Balan ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Abdominal Cavity ◽  
Clinical Signs ◽  
Laboratory Diagnosis ◽  
Ovarian Tumors ◽  
Diagnostic Methods ◽  
Diagnosis And Treatment ◽  
Ca 125 ◽  
Benign Ovarian Tumor ◽  
Mucinous Ovarian Tumors

Ovarian tumors occupy a special place in gynecological pathology due to their great diversity, diagnostic difficulties, specifying their evolutionary nature, establishing the prognosis and treatment. Ovarian mucinous tumors are a group of rare formations, with a cell of as yet undefined origin, but with an apparent progression from benign to borderline and carcinoma. The treatment of a benign ovarian tumor is surgical. Material and methods. The research in question was performed on a group of 50 patients, who were treated in the gynecology department of the IMSP Oncological Institute of the Republic of Moldova, with the diagnosis of mucinous ovarian tumors. Results. The study analyzed data on the diagnosis and treatment of mucinous ovarian tumors. The clinical diagnosis showed a unilateral ovarian involvement in 41 cases (82%) compared to the bilateral one registered in 9 patients (18%). All tumors were large and irregularly shaped. In the case of laboratory diagnosis in assessing the benign or malignant tumor potential, the tumor marker CA-125 was performed, in 41 patients the index was within the norm range from 0-35U / ml and only in 9 cases were there insignificant increases of 50-100U / ml. Ultrasonographic diagnosis is an important method in detecting mucinous ovarian tumors. The treatment of patients is surgical and, depending on the appearance of the tumor intraoperatively and age, they had a radical or less radical character. Conclusions. The most common clinical signs were fullness in the pelvis, dysuria, pain in the lumbar or sacral region. As usual, the mucous ovarian tumors are large. The CA-125 tumor marker was in most cases within the normal range. Imaging investigations are informative and some of them applied to all patients in the study. Endoscopic diagnostic methods are less informative in mucinous ovarian tumors due to bulky formations and the risk of effusion of the mucin into the abdominal cavity.

scholarly journals Risk of recurrence of malignant tumors of the ovaries and levels of tumor markers НЕ-4 and СА-125

2020 ◽  
Vol 28 (4) ◽  
pp. 364-373
Author(s):  
О. М. Sukhina ◽  
K. V. Nemaltsova ◽  
V. S. Sukhin
Keyword(s):  
Treatment Outcomes ◽  
Tumor Markers ◽  
Ovarian Neoplasms ◽  
Malignant Tumors ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Recurrence Rates ◽  
Improve Treatment ◽  
Significant Difference ◽  
One Year

Background. Timely diagnosis of recurrence of malignant tumors of the ovaries can improve treatment outcomes. Purpose – determine the feasibility of using the tumor marker HE-4 in case of recurrence of malignant ovarian tumors. Materials and methods. To analyze the levels of HE-4 and CA-125 in patients with recurrence of malignant ovarian tumors and determine the feasibility of using HE-4 at this stage of monitoring, 29 patients with known indicators of HE-4 and CA-125 at the time of recurrence and their baseline data were selected. Results and discussion. The paper presents the results of the study of the HE-4 and CA-125 tumor markers levels in 29 patients with a proven recurrence of malignant ovarian neoplasms depending on the timing of its appearance – up to 12 months (n = 9), 13–24 months (n = 11) and after 24 months (n = 9). The values of the tumor-associated HE-4 marker were decreased during the relapse compared to baseline expression levels. When analyzing of the HE-4 serum, their significant difference was revealed only in the event of relapse in the period of up to one year (1207.00 pmol/l) from recurrence rates in the periods of 13–24 and of over 24 months (567.00 and 655.50 pmol/l, respectively). Conclusions. Only the baseline expression of HE-4 is prognostically significant for determining the timing of recurrence of ovarian malignancies.

Preoperative Measurement of Cancer Antigen 125 (CA 125) in the Differential Diagnosis of Ovarian Tumors

1989 ◽  
Vol 28 (4) ◽  
pp. 471-473 ◽  
Author(s):  
O. Mogensen ◽  
B. Mogensen ◽  
A. Jakobsen ◽  
A. Sell
Keyword(s):  
Differential Diagnosis ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen

scholarly journals Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women

1999 ◽  
Vol 15 (4) ◽  
pp. 259-267 ◽  
Author(s):  
Ayşe Binnur Erbağci ◽  
Necat Yilmaz ◽  
Irfan Kutlar
Keyword(s):  
Menstrual Cycle ◽  
Tumor Markers ◽  
Normal Function ◽  
Ca 125 ◽  
Diagnostic Efficiency ◽  
Healthy Women ◽  
Healthy Female ◽  
Serum Cea ◽  
Cycle Dependent

Information on menstrual cycle dependent variation of tumor markers in healthy women is a subject of diagnostic efficiency and has an impact in elucidating the normal function of these markers. In this study midfollicular and midluteal concentrations of serum CEA, AFP, CA 19-9, CA 125, CA 15-3 and their relations with LH, FSH, prolactin, estradiol and progesterone were evaluated during ovulatory cycles in a group of 23 healthy female individuals. Samples were collected on the 7th and 21st day of the same menstrual cycle. Tumor marker and hormone concentrations were determined with chemiluminescence or electrochemiluminescence EIA methods. A significant phase-dependent difference was observed for CA 15-3, midluteal concentrations (mean ± SEM; 26.33 ± 1.56 U/ml) higher than the midfollicular (mean ± SEM; 19.27 ± 1.49 U/ml) concentrations (p < 0.001). But an obvious difference for other tumor markers investigated did not exist. Significant correlations of follicular and luteal CA 125 levels with body mass index of the subjects were observed (r:0.52, p < 0.05 and r:0.57, p < 0.005, respectively).CA 15-3 antigen is a product of the MUC-1 gene which is expressed in abundance by endometrial epithelial cells in the secretory phase of the menstrual cycle which may be the potential source of variability. The association of CA 125 levels with obesity suggests a possible role of adipose tissue in CA 125 metabolism. In conclusion our data suggest that in healthy women serum CA 15-3 levels are significantly elevated in the midluteal phase of the menstrual cycle compared to midfollicular phase. Therefore, consideration of menstrual cycle dependent variability for CA 15-3 appears indicated in interpretation of individual results.

Sign in / Sign up

Export Citation Format

Share Document